For Immediate Release
FUJIFILM Diosynth Biotechnologies SHOWCASES COMPREHENSIVE SERVICES AT 2014 BIO INTERNATIONaL CONVENTION
Morrisville, N.C., June 11, 2014 (Booth #1127) – FUJIFILM Diosynth Biotechnologies U.S.A., Inc., an industry-leading biologics contract manufacturing organization, will be featuring its comprehensive services at the 2014 BIO International Convention that will help biopharmaceutical and biotech companies meet production requirements. The convention will take place on June 23-26 at the San Diego Convention Center in San Diego, California.
“As a full service contract manufacturing organization, we can meet our partners’ needs at every stage of the product lifecycle,” said Stephen Spearman, Ph. D., MBA, president, FUJIFILM Diosynth Biotechnologies, U.S.A, Inc. “At Fujifilm, we offer our experience to develop fast-track processes from gene to early phase clinical product. We ensure these processes provide a secure regulatory route through to validation and commercial manufacture.”
Fujifilm offers an extensive breadth of process development and cGMP manufacturing experience to meet its customers’ needs at every stage of the product lifecycle, from efficient protein expression, process design and GMP manufacture, through to process validation and commercial production. Fujifilm services include cell line development (CHO and Microbial Expression Systems), upstream and downstream process development, analytical/formulation development, process characterization, cGMP microbial and cell culture.
The BIO International Convention brings thousands of biotechnology leaders together for one week of intensive, networking activity where new opportunities are identified and promising partnerships begin. To schedule a meeting with Fujifilm representatives, please submit requests via the BIO One-on-One Partnering System or to email@example.com. For more information, please visit: www.fujifilmdiosynth.com.
FUJIFILM Diosynth Biotechnologies U.S.A., Inc. is an industry-leading Biologics Contract Manufacturing Organization located in Research Triangle Park, North Carolina. Fujifilm Diosynth has over twenty-five years of combined experience in the development and manufacturing of recombinant proteins, vaccines, monoclonal antibodies, among other large molecules expressed in a wide array of microbial, mammalian, and insect cell line systems. The company offers a comprehensive list of services from cell line development using its proprietary pAVEway™ system to process development, analytical development, clinical and commercial manufacturing. Both sites are FDA-approved for the production of commercial products. For more information, go to: www.fujifilmdiosynth.com
FUJIFILM Holdings Corporation, Tokyo, Japan brings continuous innovation and leading-edge products to a broad spectrum of industries, including: healthcare, with medical systems, pharmaceuticals and cosmetics; graphic systems; highly functional materials, such as flat panel display materials; optical devices, such as broadcast and cinema lenses; digital imaging; and document products. These are based on a vast portfolio of chemical, mechanical, optical, electronic, software and production technologies. In the year ended March 31, 2014, the company had global revenues of $23.7 billion, at an exchange rate of 103 yen to the dollar. Fujifilm is committed to environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com.
All product and company names herein may be trademarks of their registered owners.